TCON TRACON Pharmaceuticals Inc.

3.75
+0.03  (1%)
Previous Close 3.73
Open 3.70
Price To book 3.61
Market Cap 62459689
Shares 16,655,917
Volume 62,325
Short Ratio 4.57
Av. Daily Volume 144,789

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171067052
  2. CT ORDER - Confidential treatment order 171043737
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015792
  4. 8-K - Current report 171014699
  5. 8-K - Current report 17982885

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due 2H 2017.
TRC253
Prostate cancer
Phase 2 trial initiation announced July 25, 2017.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with data due early 2018.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line PFS data due later in 2017.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 4Q 2017.
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2017.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 data due late 2016 according to 10Q filed November 2016. As of January 9, 2016, data have not been released and no mention of the trial was made in its January 9 presentation.
TRC105
Soft tissue sarcomas

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171067052
  2. CT ORDER - Confidential treatment order 171043737
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015792
  4. 8-K - Current report 171014699
  5. 8-K - Current report 17982885
  6. CT ORDER - Confidential treatment order 17928418
  7. 8-K - Current report 17914752
  8. 8-K - Current report 17874123
  9. 424B3 - Prospectus [Rule 424(b)(3)] 17831738
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831528